Longitudinal Assessment of Parotid Function in Patients Receiving Tomotherapy for Head-and-Neck Cancer

Voordeckers, Mia; Everaert, Hendrik; Tournel, Koen; Verellen, Dirk; Baron, Ilan; Esch, Gretel Van; Vanhove, Christian; Storme, Guy

doi:10.1007/s00066-008-1836-0

Cited by 30 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, a mean dose of about 26 Gy to the parotid gland is the generally accepted threshold to preserve salivary flow. This dose level has been confirmed by several groups [9,25,28,33]. As different dose distributions can result in the same mean organ dose, threshold dose levels have been also recommended for partial volumes of the parotid gland [9,27].…”

Section: Introductionsupporting

confidence: 49%

Investigations on Parotid Gland Recovery after IMRT in Head and Neck Tumor Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 49%

Investigations on Parotid Gland Recovery after IMRT in Head and Neck Tumor Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…13 Arc therapy reduces IMRT delivery time from 20 minutes to fewer than 5 minutes, while optimizing dose homogeneity and normal tissue sparing, [14][15][16][17][18][19][20][21][22][23][24][25] including parotid gland sparing. 26 Stereotactic fractionated RT allows for the generation of x-ray beams from a single electronic source, which can be rotated or moved around a central focus. Linear acceleratorbased stereotactic body RT may be used for multisession head and neck irradiation.…”

Section: Chemoradiation Therapymentioning

confidence: 99%

Oral complications of cancer and cancer therapy

Epstein

Thariat

Bensadoun

et al. 2012

CA A Cancer J Clinicians

412

356

View full text Add to dashboard Cite

Answer questions and earn CME/CNEOral complications resulting from cancer and cancer therapies cause acute and late toxicities that may be underreported, underrecognized, and undertreated. Recent advances in cancer treatment have led to changes in the incidence, nature, and severity of oral complications. As the number of survivors increases, it is becoming increasingly recognized that the aggressive management of oral toxicities is needed to ensure optimal long‐term oral health and general well‐being. Advances in care have had an impact on previously recognized oral complications and are leading to newly recognized adverse effects. Here, the authors briefly review advances in cancer therapy, including recent advances in surgery, oral care, radiation therapy, hematopoietic cell transplantation, and medical oncology; describe how these advances affect oral health; and discuss the frequent and/or severe oral health complications associated with cancer and cancer treatment and their effect upon long‐term health. Although some of the acute oral toxicities of cancer therapies may be reduced, they remain essentially unavoidable. The significant impact of long‐term complications requires increased awareness and recognition to promote prevention and appropriate intervention. It is therefore important for the primary oncologist to be aware of these complications so that appropriate measures can be implemented in a timely manner. Prevention and management is best provided via multidisciplinary health care teams, which must be integrated and communicate effectively in order to provide the best patient care in a coordinated manner at the appropriate time. CA Cancer J Clin 2012. © 2012 American Cancer Society.

show abstract

“…Using HT in HNC has led to better sparing of OARs, especially parotid glands [28]. An important question remains: does sparing of critical organs compromises target coverage and patient outcome?…”

Section: Introductionmentioning

confidence: 99%

Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer

Farrag

Voordeckers²,

Tournel³

et al. 2010

Strahlenther Onkol

Self Cite

View full text Add to dashboard Cite

show abstract

Longitudinal Assessment of Parotid Function in Patients Receiving Tomotherapy for Head-and-Neck Cancer

Abstract: With the use of heLical tomography the parotid gland function can largely be preserved since the mean dose to the entire gland as well as glandular volume receiving >26 Gy can be reduced.

Cited by 30 publications

References 35 publications

Investigations on Parotid Gland Recovery after IMRT in Head and Neck Tumor Patients

Investigations on Parotid Gland Recovery after IMRT in Head and Neck Tumor Patients

Oral complications of cancer and cancer therapy

Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer

Contact Info

Product

Resources

About